Results from a phase III trial demonstrated the clinical benefit of using PD-1 inhibitor Libtayo (cemiplimab), in combination with a physician’s choice of platinum-doublet chemotherapy, in the treatment of patients with locally advanced or metastatic non-small cell lung cancer, irrespective of histology and across all PD-L1 expression levels.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
